Blue Jet Healthcare Limited has reported a strong financial performance for Q3 FY25, with revenue from operations reaching ₹3,184 mn, marking a 90.9% year-on-year (YoY) increase. The company’s EBITDA stood at ₹1,240 mn, reflecting a 127.2% YoY growth, while the EBITDA margin expanded by 630 basis points to 39.0%.
The company recorded its highest-ever Profit After Tax (PAT) for a quarter at ₹990 mn, an impressive 208.3% YoY increase. PAT margin also improved significantly to 31.1%, up from 19.3% in Q3 FY24.
Key financial highlights for Q3 FY25:
- Revenue: ₹3,184 mn (YoY growth of 90.9%)
- EBITDA: ₹1,240 mn (YoY growth of 127.2%)
- EBITDA Margin: 39.0% (YoY expansion of 630 bps)
- PAT: ₹990 mn (YoY growth of 208.3%)
- PAT Margin: 31.1% (YoY expansion of 1,180 bps)
For the nine months ended December 31, 2024, the company’s revenue stood at ₹6,895 mn, reflecting a 30.7% YoY increase, while EBITDA grew 35.0% YoY to ₹2,378 mn.
Growth Drivers:
- Increased sales of Pharmaceutical Intermediates and High Intensity Sweeteners
- Cost optimization measures leading to improved profitability
- Commissioning of a new manufacturing block at Ambernath, expected to drive future growth
Commenting on the results, Managing Director Shiven Arora stated:
“Blue Jet Healthcare delivered remarkable growth, achieving record revenue and PAT. The company’s operational efficiencies and strategic investments position it for continued success despite industry challenges.”
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
